WFL 0.00% 0.3¢ wellfully limited

obj lodges patent over new energy driven drug deli

  1. 20,451 Posts.
    lightbulb Created with Sketch. 269
    0.0
    2000.0
    4000.0
    6000.0
    8000.0
    10000.0
    12000.0
    0 60 120 180 240
    Time (min)
    Cumulative amt ALA
    (ug/cm2)
    Dermaportation
    Passive
    Thursday, 9 February 2006
    OBJ LODGES PATENT OVER NEW ENERGY DRIVEN

    ===================================================
    OBJ Limited (OBJ) announced today that provisional specifications had been lodged
    with the Australian patent office covering a new active drug delivery technique. The
    new technology, which is designed to influence the behavior of drug molecules, is in
    addition to the company’s existing dermal permeability technology which controls the
    barrier effect of skin.
    The new intellectual property expands the capabilities of the company’s drug delivery
    platforms and opens new opportunities in low concentration, short term and long term
    active drug patch products.
    The new “energy-drive” technique “pushes” drug molecules, providing far greater levels
    of control over drug availability and blood plasma levels than previously thought
    possible. The new technique works in parallel with the company’s existing technology
    and provides the dual benefits of rapid initial drug availability with controlled
    transdermal diffusion.
    Normally, drug molecules migrate through the skin because of differences in
    concentration between the medication and the body. Molecules will move from a higher
    concentration area to the lower, in a process known as passive diffusion. With many
    drugs, passive diffusion is too slow, too difficult to control, unsuited to drugs with large
    molecular weights or needing to be delivered in low concentrations over extended
    periods of time.
    The new OBJ technology exploits a number of electrokinetic and thermodynamic
    principals to create the first wireless active delivery system that provides separate
    control over diffusion and skin permeability.
    The graphs below, produced by the Western Australian Biomedical Research Institute,
    demonstrates the clear differences between the passive delivery of low concentration
    drugs and the company’s Dermaportation system. Passive diffusion, even after 4
    hours, does not achieve detectable levels through human skin, however
    Dermaportation shows a strong early energy delivery phase followed by controlled
    permeability changes to the skin itself.
    Cumulative amount of
    the oncology drug
    5-ALA penetrating
    human epidermis
    following application of
    a 2% solution with
    Dermaportation (0 - 4
    h) or passive diffusion:
    mean ± sem, n = 4/3
    OBJ will continue to expand its core drug delivery technologies with a view to
    developing rapid-onset, sustained and low concentration drug delivery products.
    END:
    Background to the Announcement
    OBJ Limited is a drug delivery company, specializing in electronic “drug patch”
    technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds
    to be delivered more effectively and more efficiently through-the-skin.
    The OBJ Dermaportation system has been shown to manage and control the
    transdermal delivery of a broad range of drugs and therapeutic agents ranging from
    small difficult molecules such as Caffeine, through to large macro-globular proteins
    drugs such as vaccines.
    OBJ’s technology has been independently proven in both in-vitro and in-vivo studies
    and can manage a broader range of molecular sizes, structures and valencies than
    other active or passive drug delivery systems.
    OBJ has been successful in
    managing the through-the-skin
    delivery of drugs used in the
    inflammation, pain, cancer and
    cosmetic fields.
    OBJ’s technology is low cost, and
    can be incorporated into reusable
    drug patches, (as illustrated)
    disposable single use drug patches
    and in a range of packaging
    systems for OTC and retail use.
    Sustainable Benefits
    Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins,
    vaccines, anti-bodies and anti-aging molecules has long been the desire of the
    pharmaceutical industry. It would provide economic, safety and efficacy benefits to the
    pharmacology, medical, veterinary and cosmetic industries. Side effects could be
    reduced by localized delivery and programmed delivery rates. Needle stick injuries and
    needle disposable problems could be eliminated while the reduction in the level of skill
    required for application could significantly reduce total cost of many health
    programmes. These clear commercial benefits may only be achievable if the skin’s
    natural barrier effect can be overcome.
    OBJ is the first company to create a broad spectrum through-the-skin delivery system
    that is kind to the skin, completely reversible, yet can handle drugs range from the
    small difficult molecules up to the largest and most complex proteins and anti-bodies.
    OBJ manages an extensive IP portfolio and prosecutes patent applications throughout
    the world.
    Independence of Results
    OBJ contracts its drug and technology testing programs to independent and respected
    organisations, such as Western Australian Biomedical Research Institute, Western
    Australian Institute for Medical Research, Curtin University of Technology and Murdoch
    University. The high level of independence and international accreditation means that
    the results attributable to OBJ’s proprietary technology can be published and presented
    at major medical and scientific conferences and forums.
    For more information:
    Jeffrey Edwards
    Phone: +61 9 944 33011 Mobile: 041 791 2211 E-mail: [email protected]
    OBJ Limited (ACN 056 482 636)
    Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
    Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: [email protected]
 
watchlist Created with Sketch. Add WFL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.